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Purpose/Objective: Standard management of low rectal 
cancer is radical surgery often combined with pre-operative 
External Beam Radiotherapy (EBRT) ± chemotherapy. Despite 
advances in surgical techniques permanent stoma formation 
can be unavoidable. Contact radiotherapy (CBT) offers an 
alternative to surgery. Potentially operable patients must 
understand close follow up is required as the risk of local 
recurrence is greater, though with salvage surgery overall 
survival appears not to be affected. St Luke’s Cancer Centre 
offers this treatment via a 50kV orthovoltage machine 
(Ariane, Derby, UK). This service commenced in April 2014. 
We report response assessment using MRI in potentially 
operable patients with a minimum of 3 months follow up. 
Materials and Methods: 15 patients have been treated to 
date. Median age is 62 years (51 to 87 years), 10 male and 5 
female patients were treated. Clinical staging ranged from 
T2N0 to T3N1. All cancers were histologically confirmed 
adenocarcinomas. Treatment was planned via the 
multidisciplinary team. One patient was excluded from this 
analysis as who developed progressive disease and was 
offered immediate surgery.  
All patients received EBRT 45Gy/25 fractions with a CBT 
boost of 90Gy in 3 fractions. Median duration of CBT boost 26 
days (24-30 days). 
Results: 3 Patients with tumours <3cm at presentation had 
CBT prior to EBRT. 12 patients had CBT boost post EBRT.  
Median follow up is 4 months (3-7 months). 14 Patients have 
had 3 month MRI scans, all of which show radiological 
complete response with no tumour seen (TRG1). 
Complications: Acute toxicity is recorded at subsequent clinic 
visits. This treatment is well tolerated, and only Grade 1 
diarrhoea and rectal bleeding have been reported. 
Conclusions: With appropriate counselling patients can make 
an informed decision to have stoma-sparing treatment 
potentially at the expense of an increased local failure rate. 
Early results show good response to treatment with 
acceptable toxicity. Complete resolution of tumour was seen 
in all cases where treatment was completed as planned. 
These patients will remain under follow up for tumour 
control and late toxicity. 
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Purpose/Objective: to present the treatment regimen and 
contention method, used to treat surgically mistreated or 
recurrent facial skin cancer and skin metastatic breast 
lesions, with HDR Plesiotherapy (PT) 
Materials and Methods: a total of 170 treatments were 
performed in 15 patients: 9 with basal or squamouscell 
carcinoma (1 was treated twice); 6 with progressive 
extension of thoracic skin breast metastasis (1 was treated 
twice). These last patients were treated in and out of the 
previously irradiated zone (2 to 7 years). The planning 
method was identical for all the patients. One or several 
zones (1-6) were carefully delineated with a radiopaque 
marker, then covered with a moulded thermoplastic facial or 
thoracic mask for strict immobilization and reproductibility; 
the first bolus plaque was applied on the mask and 6 Fr 
plastic tubes were placed 10 mm apart above the treatment 
zone, and immobilized by 2 more plaques. The dosimetry 
done with CT images allows for the selection of the depth 
from 3-6 mm of the prescribed dose. For all patients, the 
total delivered dose was 40 Gy in 5 weeks, 10 fractions, 
twice a week. Every patient had a photo file with pre-
treatment, simulation, reactions during HDR PT, and follow 
up pictures, in order to afford an eventual re-treatment. 
Results: all 15 patients, including the 2 re-treated for vicinity 
cancer progression, are macroscopically disease free after 
HDR PT with follow up times of 4 to 26 months. Two patients 
with wide thoracic multi irradiated zones had a 1 week 
treatment interruption due to radioepithelitis. Complete 
healing occured 2 weeks after the end of PT, but 1 thoracic 
patient needed 7 weeks. The final cosmetic results were also 
dependent on the previous treatment (surgery or RT): 8 
excellent, 1 good for the facial group; 3 good, 2 medium, 1 
bad for the thoracic group. 
Conclusions: HDR PT is a good treatment for primary skin 
cancer and skin breast metastatsis with progressive 
extension. The three dimensional dosimetry and contention 
mask ensure the reproductibility of the delineated zone at 
the chosen depth. This precision allows for re- treatments in 
close vicinity even with an irregular shape. With this regimen 
we achieved a good oncological control and cosmetic results 
with a low complication rate. New superficial locations are 
now in experience. 
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Purpose/Objective: To evaluate clinical value of HDR 
brachytherapy in patients with non-operable recurrent 
malignant soft tissue sarcomas (MSTS) and role of 99mTc-MIBI 
SPECT-CT imaging in therapy planning and monitoring of its 
efficacy 
Materials and Methods: The study group consisted of 9 
patients with RSTS that were inoperable (2 patients with 
pelvic tumours) or considered as candidates for amputation 
(7 patients with MSTS of extremities). Tumor volume varied 
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from 51 to 1783 ml. HDR brachytherapy was performed in 
order to reduce tumor volume and to decrease invasive 
potential of MSTS during non-compartmental surgery. After 
SPECT-CT preplanning, CT guided insertion of plastic needles 
and final HDR therapy planning 3 fractions of 7 Gy (with at 
least 5-6 hours of interfractional interval) were delivered in 
first 4 patients and 3 fractions of 8Gy – in last 5 cases.  
SPECT-CT with 99mTc-MIBI was performed before treatment 
in order to visualize viable tumour subregions and every 3-4 
weeks after brachytherapy for monitoring its efficacy and in 
order to determine optimal time for surgical intervention 
Results: In 6 of 7 patients with MSTS of extremities HDR 
brachytherapy converted treatment strategy from 
amputation to limb preserving surgery. In 2 of these 6 
patients amputations were performed 3-6 months after 
primary treatment. One of 2 patients with pelvic MSTS was 
considered operable 3 months after HDR brachytherapy. 
Postoperative consolidation external beam radiotherapy 
(45Gy) was performed in this case without early and late 
complications. 
SPECT-CT with 99mTc-MIBI effectively visualized viable and 
hypoxic-necrotic subregions of MSTS. After treatment SPECT-
CT correctly determine tumour regression in all 2 patients 
with pathomorphological complete or nearly complete (>90%) 
response, all 2 cases with partial pathologic response and 3 
observations of stabilization or tumour progression. All 4 
patients with complete or partial SPECT-CT response 
underwent limb saving surgery and are in remission. 
Conclusions: In patients with recurrent MSTS HDR interstitial 
brachytherapy can increase frequency of limb saving 
operations and converted inoperable tumours to operable. 
99mTc SPECT-CT can accurately determine response of MSTS 
to HDR brachytherapy and can be used for monitoring of 
treatment efficacy. 
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Purpose/Objective: To evaluate the treatment benefit of 
using custom mold surface applicators, computer-optimized 
high dose rate brachytherapy for cutaneous lymphoma. 
Materials and Methods: Seven patients with T cell lymphoma 
and one patient with anaplastic large cell lymphoma were 
treated at our department. A total of 41 sites where treated, 
two of which were retreat. The skin areas to be treated were 
delineated with radiopaque wires. Individual complex custom 
molds were created using Aquaplast thermoplastic base 
(QfixTM) and Freiburg catheters. A CT scan was performed 
with radio-opaque dummy markers placed inside the 
catheters, in order to conduct accurate 3D treatment 
planning. The data was then transferred to the brachytherapy 
planning system. A dose of 800cGy in 2 fractions was used for 
palliation. Higher doses like 2000cGy in 8 fractions were used 
for more extensive disease or re-treatment and up to 
4000cGy in 20 fractions with the goal of long term response. 
A computerized treatment volume was created that had a 
dimension identical to the skin area defined by the 
radiopaque wires and a thickness equal to the prescription 
depth of 3 mm. 
Results: The median follow up was 17.9 months (range 1.6 to 
43.3 months). Seven of the eight patients reported complete 
resolution of pain for a total of 39 treated sites. One patient 
recurred in both sites treated with HDR and also in sites 
treated with electron beam therapy. She was re-treated with 
a higher dose, her recent biopsies shows mycosis fungoides.  
 
 
The RTOG skin morbidity scale was used to assess the 
cosmetic outcome. For all sites treated with 800cGy no grade 
1-4 toxicity was noted. In one site treated with 3000cGy a 
grade 1 late reaction in the form of a very discreet skin 
tanning and dryness was seen. The two re-treated sites had a 
late RTOG scale of 2: some patch atrophy, pigmentation 
changes, very dry flaky skin. 
 
 
 
Conclusions: Skin lymphomas can be very aggressive and 
debilitating if not treated. Fortunately they have a very good 
response to radiation treatments. For complex geometries, 
including curved and large surfaces, HDR brachytherapy 
techniques using custom molds will provide better coverage 
when compared to external beam or electron therapy. This 
technique provides excellent dose conformity, while 
delivering a lesser dose to adjacent normal organs. The 
clinical outcome was excellent with most patients describing 
resolution of pain and good cosmetic outcome. 
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